Table 3.
Basic characteristics of MS patients with and without COVID-19 infection during the Omicron wave
| Variables | Number (%) | P-value | |
|---|---|---|---|
| Patients who developed COVID-19 | Patients who did not develop COVID-19 | ||
| Number | 76 | 98 | – |
| Age (mean ± SD) | 36.7 ± 8.5 | 37.7 ± 9.4 | 0.501 |
| Age > 50 | 3 (3.9%) | 10 (10.2%) | |
| Age ≤ 50 | 73 (96.1%) | 88 (89.8%) | |
| Sex | 0.077 | ||
| Female | 63 (82.9%) | 70 (71.4%) | |
| Male | 13 (17.1%) | 28 (28.6%) | |
| Addiction | 0.185 | ||
| Yes | 10(13.2%) | 7 (7.1%) | |
| No | 66 (86.8%) | 91 (92.9%) | |
| Type of MS | 0.004 | ||
| CIS | 4 (5.3%) | 8 (8.2%) | |
| RRMS | 55 (72.4%) | 71 (72.4%) | |
| PPMS | 0 (0%) | 10 (10.2%) | |
| SPMS | 17 (22.4%) | 9 (9.2%) | |
| Duration of MS (mean ± SD) (year) | 11.25 ± 7.22 | 10.13 ± 6.56 | 0.292 |
| Minimum | 1 | 1 | |
| Maximum | 31 | 35 | |
| DMTs | 0.821 | ||
| Rituximab | 30 (39.5%) | 29 (29.6%) | |
| Ocrelizumab | 6 (7.9%) | 10 (10.2%) | |
| Fingolimod | 9 (11.8%) | 9 (9.2%) | |
| Dimethyl fumarate | 6 (7.9%) | 7 (7.1%) | |
| Teriflunomide | 2 (2.6%) | 1 (1%) | |
| INFβ-1a IM | 3 (3.9%) | 5 (5.1%) | |
| INFβ-1a SC | 4 (5.3%) | 10 (10.2%) | |
| INFβ-1b SC | 2 (2.6%) | 6 (6.1%) | |
| Glatiramer acetate | 6 (7.9%) | 11 (11.2%) | |
| Azathioprine | 2 (2.6%) | 2 (2%) | |
| Other | 2 (2.6%) | 5 (5.1%) | |
| None | 4 (5.3%) | 3 (3.1%) | |
| Underlying disease | 0.105 | ||
| Cancer | 0 (0%) | 3 (3.1%) | |
| Hypothyroidism | 3 (3.9%) | 0 (0%) | |
| Hypertension | 4 (5.3%) | 1 (1%) | |
| Heart disease | 1 (1.3%) | 0 (0%) | |
| Diabetes mellitus | 1 (1.3%) | 0 (0%) | |
| Allergic reactions | 2 (2.6%) | 5 (5.1%) | |
| Others | 9 (11.8%) | 10 (10.2%) | |
MS multiple sclerosis, CIS clinically isolated syndrome, RRMS relapse-remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, DMT disease-modifying treatment, INFβ interferon beta, IM intramuscular, SC subcutaneous